McQuay H: Opioids in pain management. Lancet. 1999; 353: 2229-2232.
2.
Bonica JJ: Treatment of cancer pain: Current status and future needs. Advances in Pain Research & Therapy. 1985; 9: 589-616.
3.
Portney RK, et al.: Transdermal fentanyl for cancer pain. Anesthesiology. 1993; 78: 36-43.
4.
Mercadante S, et al.: Analgesic effects of nonsteroidal anti-inflammatory drugs in cancer pain due to somatic or visceral mechanisms. Journal of Pain & Symptom Management. 1999; 17(5): 351-356.
5.
Gordon RL: Prolonged central intravenous ketorolac continuous infusion in a cancer patient with intractable bone pain. Annals of Pharmacotherapy. 1998; 32(2): 193-196.
6.
Gillis JC, et al.: Ketorolac: A reappraisal of its pharmacodynamic and pharmacodynamic properties and therapeutic use in pain management. Drugs. 1997; 53(1): 139-188.
7.
Silversein FE, et al.: Gastrointestinal toxicity with celecoxib vs. nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis. JAMA. 2000; 284(10): 1247-1255.
8.
Bombardier C, et al.: Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. NEJM. 2000; 343(21): 1520-1528.
9.
Simon L, et al.: Anti-inflammatory and upper gastrointestinal effects of celecoxib in rheumatoid arthritis. JAMA. 1999; 282(20): 1921-1928.
10.
Langman M, et al.: Adverse upper gastrointestinal effects of rofecoxib compared with NSAIDs. JAMA. 1999; 282(20): 1929-1933.
11.
Backonja M, et al.: Gabapentin for the symptomatic treatment of painful neuropathy in patients with diabetes mellitus. JAMA. 1998; 280(21): 1831-1836.
12.
Rowbotham M, et al.: Gabapentin for the treatment of postherpetic neuralgia. JAMA. 1998; 280(21): 1837-1842.
13.
Dallocchio C, et al.: Gabapentin vs. amitriptyline in painful diabetic neuropathy: An open-label pilot study. Journal of Pain & Symptom Management. 2000; 20(4): 280-285.
